摘要
目的研究顺铂腹腔灌注联合静脉化疗治疗胃癌腹腔转移的临床疗效。方法选择2015年4月至2018年4月上海市闵行区肿瘤医院收治的胃癌腹腔转移患者60例,按随机数字表法分为观察组与对照组各30例。对照组行静脉化疗治疗,观察组腹腔灌注顺铂联合静脉化疗治疗。对比两组治疗后临床疗效、存活时间及治疗期间不良反应发生情况,另外对比两组治疗前后欧洲癌症治疗研究组织生活质量测定量表(quality of life scale of European Organization for Research and Treatment of Cancer,EORTC QLQ-C30)评分。结果观察组治疗后有效率70.00%、控制率93.33%,显著高于对照组(43.33%、73.33%),差异有显著性(P<0.05)。两组患者治疗后均行12个月随访,期间无失访;观察组中位生存时间显著高于对照组,差异有显著性(P<0.05);观察组治疗后6、9、12个月存活率显著高于对照组,差异有显著性(P<0.05)。观察组治疗后功能评分、症状评分、整体生活质量评分、单项测量项目评分显著高于治疗前及对照组治疗后,差异有显著性(P<0.05)。两组不良反应总发生率对比,差异无显著性(P>0.05)。结论顺铂腹腔灌注联合静脉化疗治疗胃癌腹腔转移能够提高临床治疗效果及患者的生活质量,同时还能延长患者生存时间,具有较高的临床应用价值。
Objective To study the clinical efficacy of cisplatinum-intraperitoneal perfusion combined with intravenous chemotherapy in the treatment of peritoneal metastasis of gastric cancer.Method A total of 60 patients with peritoneal metastasis of gastric cancer who were treated in our hospital from April 2015 to April 2018 were selected,and were divided into observation group(n=30)and control group(n=30)by random number table method.The control group was treated with intravenous chemotherapy,and the observation group was treated with intraperitoneal DDP combined with intravenous chemotherapy.Clinical efficacy,survival time and adverse reactions during treatment were compared between the two groups.In addition,quality of life scale of European Organization for Research and Treatment of Cancer(QLQ-C30)scores of cancer patients before and after treatment were compared between the two groups.Result After treatment,the effective rate and control rate of the observation group was 70.00%and 93.33%respectively,which was significantly higher than those of the control group(43.33%and 73.33%,P<0.05).Two groups of patients were followed up for 12 months after treatment,during which there was no loss of follow-up.The median survival time of the observation group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).The survival rate of 6,9 and 12 months after treatment in the observation group was significantly higher than that in the control group(P<0.05).The functional scores,symptom scores,overall quality of life scores,and scores of individual measurement items in the observation group were significantly higher than those before and after treatment(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion DDP intraperitoneal perfusion combined with intravenous chemotherapy in the treatment of abdominal metastasis of gastric cancer could improve the clinical efficacy and quality of life of patients,but a
作者
肖谜
王妹兴
Xiao Mi;Wang Xingmei(Shanghai Minhang District Tumor Hospital,Shanghai 200240,China)
出处
《中国临床医生杂志》
2020年第8期908-911,共4页
Chinese Journal For Clinicians
关键词
胃癌
腹腔转移
顺铂
腹腔灌注
静脉化疗
Gastric cancer
Abdominal metastasis
Cisplatin
Intraperitoneal perfusion
Intravenous chemotherapy
